Introduction of Oncology Devices Industry
Oncology medical devices play a vital role in the diagnosis, treatment, and monitoring of cancer by enabling accurate detection and assessment of tumors. These devices help map the location, size, and progression of cancerous cells, guiding clinical decisions across various stages of care. Commonly used technologies include MRI scanners, PET scans, and ultrasound systems, which oncologists rely on to visualize internal structures, track tumor growth, and evaluate treatment response.
(Source:https://operonstrategist.com/oncology-medical-devices-manufacturing-and-regulatory-compliance/)
Market Dynamics of Oncology Devices Market
The global oncology devices market is driven by the rising cancer prevalence, increasing demand for minimally invasive treatments, and technological advancements in imaging and therapeutic tools. For instance, according to WHO, global cancer cases are expected to rise by 77%, reaching over 35 million by 2050 from 20 million in 2022. However, regulatory challenges, high device costs, as well as reimbursement limitations pose key restraints. Meanwhile, the growing adoption of AI, robotics, and precision medicine presents significant opportunities for market expansion.
(Source:https://iris.who.int/bitstream/handle/10665/255262/9789241565462-eng.pdf)
Competitive Landscape of Oncology Devices Industry
Leading Players of Oncology Devices Industry
The leading companies in the global oncology device market maintain their dominant positions due to a strategic blend of technological innovation, global reach, diversified product portfolios, and acquisitions. Key players include:
- AngioDynamics
- Boston Scientific
- Medtronic
- Merit Medical Systems
- Terumo
- BD
- IceCure
- Profound Medical
- HealthTronics
- Siemens Healthineers
The top players such as Medtronic, Boston Scientific, BD, Terumo, and Merit Medical Systems, consistently invest in research and development to introduce cutting-edge technologies that support early cancer detection, minimally invasive treatment, and improved patient outcomes. Their deep integration into hospital systems and ability to provide end-to-end oncology care solutions further strengthen their leadership.
Other notable players include AngioDynamics, IceCure Medical, Profound Medical, HealthTronics, and Siemens Healthineers, each contributing unique strengths in niche oncology technologies. These companies are recognized for their specialized offerings in ablative therapies, image-guided interventions, and diagnostic support. Their ability to target specific cancer treatment modalities while maintaining regulatory compliance and clinical partnerships makes them important contributors to the evolving global oncology devices landscape.
(Source:https://www.angiodynamics.com/healthcare-professionals/oncology/)
Upcoming Players of Oncology Devices Industry
There are several emerging players in the Oncology Devices market that are gaining traction due to their focus on next-generation technologies, novel therapeutic approaches, and addressing unmet clinical needs. Key upcoming players are:
- Francis Medical, Inc.
- Nanoflex Robotics AG
- Tempus
- Guardant Health
- Medical Microinstruments, Inc
- Tivic Health
Francis Medical, Inc. is emerging as a key innovator in oncology devices with its water vapor ablation technology for treating prostate and kidney cancer. This minimally invasive solution provides a non-radioactive, targeted alternative to conventional therapies. Nanoflex Robotics AG is gaining attention for its magnetic navigation technology that enables precise control of microcatheters in complex endovascular and oncological interventions, potentially improving tumor targeting and reducing patient trauma.
(Source:https://nanoflexrobotics.com/our-technology/)
Additionally, Tempus is revolutionizing oncology with its AI-driven diagnostics and precision medicine platforms that integrate clinical and molecular data to personalize cancer treatment, making it a critical player in data-powered oncology solutions. Other notable emerging companies include Guardant Health, Medical Microinstruments, Inc and Tivic Health.
The Cardiovascular Medical Devices Market is generally considered to be moderately concentrated, with a mix of large global players and numerous regional and niche companies. The top 5–7 players control 50–60% of the global market, particularly in radiotherapy and diagnostic oncology devices.
Additional Insights of Oncology Devices Industry
Technological Developments of Oncology Devices Market
Image-Guided Radiation Therapy (IGRT):
IGRT uses advanced imaging technologies such as CT, MRI, and PET scans during radiation treatment to enhance precision. Devices like Varian’s TrueBeam system allow oncologists to target tumors with sub-millimeter accuracy, minimizing damage to surrounding tissues. This technology is particularly effective for treating prostate, brain, and lung cancers where precision is critical.
Radiofrequency Ablation (RFA) and Microwave Ablation (MWA):
RFA and MWA deliver heat to cancerous tissues to destroy tumors without major surgery. Companies like AngioDynamics offer the StarBurst Xli-enhanced RFA system, widely used in liver and kidney tumors. These technologies are gaining traction for patients who are not candidates for surgical resection due to age or comorbidities.
Robotic-Assisted Surgical Systems:
Robotic systems like the da Vinci Surgical System enable minimally invasive procedures with improved dexterity and control. These systems are revolutionizing oncology surgeries, particularly for prostate and gynecologic cancers. Their ability to minimize incision size and recovery time enhances patient outcomes and hospital efficiency.
Artificial Intelligence in Diagnostics and Planning:
AI is transforming cancer care through predictive diagnostics and personalized treatment plans. Solutions like IBM Watson for Oncology and Siemens’ AI-Rad Companion help interpret complex imaging and pathology data, recommending optimal therapy options based on clinical evidence. This accelerates diagnosis and supports precision oncology.
Liquid Biopsy and Genomic Profiling Devices:
Liquid biopsies analyze circulating tumor DNA (ctDNA) from blood samples for non-invasive cancer detection and monitoring. Companies like Guardant Health and Foundation Medicine are advancing this field. These devices aid in identifying actionable mutations, allowing for personalized drug targeting, especially in lung and breast cancer cases.
Impact of 2025 US Tariffs on Oncology Devices Market
The proposed 2025 U.S. tariffs could negatively impact the expanding oncology devices market, driven by an aging population and rising chronic illness rates. A potential 60% tariff on Chinese imports may disrupt supply chains, affecting around 13.6% of U.S.-marketed medical devices made in China.
If semiconductor components are targeted, production costs for devices, is expected to rise regardless of U.S. assembly. This may force manufacturers to pass increased costs onto consumers and healthcare providers, straining budgets and limiting access to essential oncology technologies. Larger firms like Siemens Healthineers and BD may absorb or offset these costs through scale and supply shifts, but smaller niche players face reduced competitiveness or potential exit.
Pricing Analysis of Oncology Devices Market
Pricing in the oncology devices market is highly influenced by innovation, regulatory status, and procedural complexity. Devices like Varian’s radiotherapy systems or Novocure’s Optune system command premium prices due to their advanced features and proven clinical efficacy. However, in emerging markets, price sensitivity drives demand for cost-effective alternatives. Reimbursement compatibility and bundled care models also impact device pricing strategy significantly.
(Source:https://www.ncbi.nlm.nih.gov/books/NBK602918/)
Reimbursement Scenario of Oncology Devices Market
Reimbursement frameworks play a vital role in oncology device adoption, especially for high-cost therapies. For example, Medicare covers external beam radiation therapy (EBRT) under CPT codes, facilitating patient access in the U.S. Countries with nationalized healthcare, like the UK, require technology assessments by NICE. Lack of clear reimbursement pathways for emerging devices like tumor-treating fields (TTFields) are expected to delay adoption. Additionally, value-based reimbursement models are also gaining ground, linking coverage to patient outcomes.
(Source:https://www.oracle.com/health/value-based-care-models/)
Unmet Needs and Customer Expectations Analysis of Oncology Devices Market
There is an urgent need to address health policy challenges like resource allocation in cancer control plans and to leverage technological innovations to bridge global gaps in delivering equitable psychosocial cancer care. Unmet needs include real-time treatment response monitoring, integration with EHRs, and better device ergonomics.
On the other hand, clinicians seek oncology devices that reduce treatment times, minimize toxicity, and improve tumor targeting. Patients demand less invasive, home-based solutions, driving growth in wearable infusion pumps and portable radiation systems. Despite innovation, there remains a gap in affordable devices for use in low-resource and rural settings.
(Source:https://pmc.ncbi.nlm.nih.gov/articles/PMC7103815/)
Investment & Funding Scenario of Oncology Devices Market
The oncology device segment has attracted robust investor interest, driven by rising cancer incidence and demand for precision care. Venture capitalists continue to fund startups offering AI-enabled diagnostics, robotic biopsy tools, and novel energy-based ablation devices. For instance, in May 2025, PorTal Access, a Miami-based medical device company focused on advancing vascular access for cancer patients, has raised USD 7 million in Series A funding, with USD 6 million contributed by U.S. physicians including oncologists, interventional radiologists, and vascular surgeons. Moreover, government grants, particularly from NIH and EU Horizon programs, support early-stage oncology device development. M&A remains a key growth strategy.
Regulatory Framework of Oncology Devices Market
|
Region/Country |
Regulatory Authority |
Classification System |
Approval Pathways |
Recent Developments |
|
United States |
FDA – Center for Devices and Radiological Health (CDRH) |
Class I (low risk), II (moderate), III (high) |
510(k), De Novo, PMA (Premarket Approval) |
510(k) clearance is dominant (~90% of devices). Cybersecurity and SaMD (software as a medical device) are growing focus areas. |
|
European Union |
Notified Bodies under EU MDR (2017/745) |
Class I, IIa, IIb, III |
CE Mark via Notified Body (except Class I self-certification) |
EU MDR increased clinical evidence and post-market surveillance demands; grace periods extended due to system bottlenecks. |
|
China |
National Medical Products Administration (NMPA) |
Class I, II, III |
Notification (Class I), Registration (Class II/III) |
Requires local clinical trials unless exemptions apply. Heavily regulated but rapidly harmonizing with global standards. |
|
India |
Central Drugs Standard Control Organization (CDSCO) |
Class A (low), B (moderate), C, D (high) |
Registration through SUGAM portal |
Transitioning to risk-based regulatory regime; licensing mandatory for most devices from 2023 onward. |
|
Japan |
Pharmaceuticals and Medical Devices Agency (PMDA) |
General, Controlled, Highly Controlled |
Pre-market Certification, Approval, or Notification |
Rigorous but efficient with a review partner system; good market for innovative devices post-approval. |
Oncology devices are stringently regulated due to their high-risk nature. In the U.S., devices undergo FDA 510(k) or PMA clearance, depending on novelty and invasiveness. Europe’s MDR guidelines have increased compliance complexity for companies like Elekta, especially around post-market surveillance. China’s NMPA and Japan’s PMDA are aligning more with global standards, expediting market entry. Regulatory harmonization remains a challenge, but efforts like IMDRF aim to streamline global approvals.
Patent Analysis of Oncology Devices Market
|
Patent No. |
Title |
Expiry |
Assignee |
|
US9526920B2 (https://patents.google.com/patent/US9526920B2/en) |
Medical device |
2031-10-12 |
Smith and Nephew Inc |
Ecosystem Analysis of Oncology Devices Industry
Raw Material Sourcing
Raw materials form the foundation of oncology medical devices, ranging from polymers to specialty coatings and biocompatible materials. Companies like 3M, DuPont, BASF, and Celanese supply critical inputs such as medical-grade plastics, elastomers, and adhesives used in catheters, biopsy tools, and implantable devices. Reliable sourcing ensures product safety, regulatory compliance, and uninterrupted manufacturing workflows in a highly regulated, precision-driven industry.
(Source:https://plastics-rubber.basf.com/emea/en/performance_polymers/industries/pp_medical_technology)
Manufacturers
Global leaders like BD, Medtronic, Abbott, Terumo, and Boston Scientific design and manufacture a wide range of oncology devices, including drug delivery systems, infusion pumps, and ablation technologies. These manufacturers drive innovation, ensure stringent quality control, and comply with regulatory standards. Their expertise and scale enable cost-effective production and rapid global distribution, which is vital in addressing rising cancer prevalence and evolving treatment protocols.
(Source:https://www.bd-products.com/products/ivsets/products.php?mid=3&NON_DEDICATED=Yes&ONCOLOGY=Yes)
Distributors and Logistics
Distribution and logistics providers like McKesson, Cardinal Health, Medline, Owens & Minor, UPS, and DHL ensure timely and secure delivery of oncology devices to hospitals, clinics, and research institutions. Their role includes warehousing, inventory management, cold chain logistics, and last-mile delivery. Efficient logistics is critical in the oncology space, where device availability can directly impact treatment schedules and patient outcomes.
(Source:https://mms.mckesson.com/catalog/category?node=17161)
AI In Oncology Devices Industry
Artificial Intelligence (AI) is redefining oncology device innovation by enhancing diagnostic accuracy, accelerating clinical workflows, and enabling personalized treatment strategies. By leveraging vast datasets, including medical imaging, patient records, and genomic data, AI-integrated devices are improving early cancer detection and clinical decision-making. A notable example is Qure.ai’s qXR-LN, an FDA-cleared AI tool that identifies lung nodules through chest X-rays, significantly expanding diagnostic reach, particularly in underserved markets. The product received its 13th FDA clearance in January 2024. AI’s integration into oncology devices supports real-time monitoring, predictive analytics, and streamlined treatment planning, delivering measurable improvements in patient outcomes and operational efficiency. For healthcare providers and medtech firms alike, AI is not merely a technological upgrade, it’s a strategic differentiator that aligns with value-based care models. As the oncology device market becomes increasingly data-driven, companies investing in AI-enabled solutions are better positioned to meet rising clinical demands, reduce costs, and gain a competitive edge in a rapidly evolving healthcare landscape.
(Source:https://www.definitivehc.com/blog/ai-enabled-medical-devices)
Trade Analysis of Oncology Devices Industry
Trade analysis in the global oncology devices market offers strategic insights into the movement of high-value medical technologies across borders, reflecting shifts in demand, manufacturing capabilities, and regulatory alignment. Countries like the United States, Germany, Ireland, Switzerland, and China emerge as vital exporters of medical devices. These nations serve as highly central hubs, exerting outsized influence on global availability and pricing. For instance, the U.S. remains a leading exporter of radiation therapy equipment and minimally invasive oncology tools, driven by innovation and FDA clearances. Conversely, countries like India and Brazil show consistent import growth for infusion pumps, imaging systems, and biopsy devices, signaling rising investment in cancer infrastructure.
(Source:https://pmc.ncbi.nlm.nih.gov/articles/PMC9250171/)
Recent Developments & Strategies in Oncology Devices Industry
In May 2025, RenovoRx, Inc., a leading life sciences company advancing targeted oncology therapies, announced the issuance of U.S. Patent No. 12,290,564 by the United States Patent and Trademark Office (USPTO), effective May 6, 2025. This newly granted patent strengthens the company’s intellectual property portfolio surrounding RenovoCath, its FDA-cleared, proprietary drug-delivery device designed to deliver precision therapies directly to tumor sites, enhancing treatment efficacy while minimizing systemic toxicity.
In April 2025, University Hospitals Cleveland Medical Center entered into a strategic collaboration with Qure.ai to enhance early lung cancer detection efforts. The partnership focused on deploying Qure.ai’s FDA-cleared artificial intelligence solution, qXR-LN, which was designed to identify early signs of lung cancer through routine chest X-rays. This initiative marked a significant step toward integrating AI-driven diagnostics into clinical workflows, aiming to improve patient outcomes through faster and more accurate detection.
In January 2025, Argon Medical announced the acquisition of key assets from Accurate Medical Therapeutics, Ltd., including the SeQure and DraKon microcatheters, previously owned by Guerbet SA. This strategic move enhances Argon’s interventional oncology portfolio with advanced therapeutic microcatheter technologies.
(source:https://www.argonmedical.com/argon-medical-acquires-sequre-and-drakon-microcatheters/)
Key Conferences & Events (2025)
|
Conference |
Duration |
Location |
Description |
|
ASCO Direct Honolulu |
June 28–29, 2025 |
Alohilani Resort Waikiki Beach, Honolulu, HI |
Hosted by the American Society of Clinical Oncology, this event features in-depth education on the latest oncology research, including sessions on medical devices and diagnostics |
|
The MedTech Conference |
October 5–8, 2025 |
San Diego, CA |
A leading global medical technology event including oncology device showcases, investment forums, and regulatory sessions |
|
American Medical Device Summit |
October 15–16, 2025 |
Schaumburg, IL |
The 2025 American Medical Device Summit brings together over 250 industry leaders to explore trends in wearables, R&D, robotics, and AI, fostering innovation and collaboration in the medical device sector. |
(Source:https://www.totalhealthoncology.com/upcoming-oncology-conferences/asco-hawaii-2025)
Research & Development Analysis of Oncology Devices Industry
In 2025, R&D in the oncology medical devices market continues to focus on precision, minimally invasive technologies, and AI-driven innovations. Companies are aggressively investing to improve diagnosis, treatment, and patient outcomes in oncology care.
In May 2024, GE HealthCare launched Revolution RT, an advanced radiation therapy computed tomography (CT) system designed to elevate oncology care. The system integrated cutting-edge hardware and software innovations aimed at enhancing imaging precision while streamlining simulation workflows. The launch underscored GE HealthCare’s commitment to advancing precision medicine in radiation oncology.
In November 2024, Caris Life Sciences (Caris), a leading next-generation AI TechBio company in precision medicine, announced that the U.S. Food and Drug Administration (FDA) had approved its MI Cancer Seek assay as a companion diagnostic (CDx). This milestone approval enabled the assay to be used in identifying cancer patients eligible for treatment with specific targeted therapies. This approval marked a significant advancement in personalized oncology care by integrating AI-powered diagnostics to guide more effective, tailored treatment strategies
(Source:https://www.carislifesciences.com/about/news-and-media/caris-welcomes-mass-general-cancer-center/)
Furthermore, collaborations between medtech firms and research institutions have also accelerated, with partnerships aiming to co-develop next-gen companion diagnostics, robotics, and smart sensors tailored for oncology applications.
Case Study
Regulatory Strategy Optimization for a Complex Oncology Trial Involving a Companion Diagnostic
A global study sponsor collaborated with ICON to evaluate a novel biological treatment for oncology patients alongside standard chemotherapy across 30+ countries, including numerous EU nations. As part of the trial, patients provided tissue samples to assess the performance of a companion diagnostic (CDx) assay. With the implementation of the EU’s IVDR adding complexity to the Clinical Trials Directive (CTD), regulatory inconsistencies between nations posed significant challenges—especially with overlapping documentation and staggered submission timelines.
ICON devised a tailored regulatory submission strategy accounting for both IMP and IVD aspects, ensuring alignment with each country’s evolving IVDR compliance. By coordinating submissions, clarifying national requirements, and integrating a cover letter detailing site roles and data flow, ICON minimized regulatory queries. As a result, the study secured timely approvals with minimal delays. Effective collaboration between the sponsor, IVD manufacturer, and ICON enabled the project to advance smoothly and meet key development milestones.
Conclusion
The global oncology devices market stands at a pivotal crossroads, driven by rising cancer incidence, early diagnosis emphasis, and advancements in minimally invasive treatment technologies. There is a growing convergence of digital health, AI-enabled imaging, and targeted delivery systems reshaping patient outcomes and care pathways. However, disparities in reimbursement, regulatory complexities, and high R&D costs remain key barriers, particularly in low- and middle-income countries. With increasing investment in precision oncology and value-based care models, the market is transitioning from volume-driven sales to outcome-based solutions. Companies that align innovation with accessibility and clinical impact is anticipated to lead the next wave of oncology device evolution.
List of Oncology Devices Industry Reports
Oncology Devices Industry Clients Worldwide
